Articles by Anna Rose Welch

  1. So, You Want To Be Top Earning Healthcare CEO? Shoot For Biopharma 1/21/2015

    In 2012, Pfizer’s CEO Ian Read held the title of being the highest-paid CEO of a large pharmaceutical company, bringing roughly $26 million to the bank. His salary was $21 million more than the lowest paid large pharmaceutical CEO, NovoNordisk’s Lars Rebien Soerensen, who earned $5 million, Bloomberg reported in the spring of 2013. However, some more numbers released in June of 2014 are showing that, in 2013, Pfizer’s Read stepped aside and earned less than what several of his CEO peers in the biopharma space are making, even though Pfizer raked in $52 billion in revenue for the year.

  2. The 2015 NSCLC Immunotherapy Race Is Already Narrowing 1/20/2015

    It’s been a productive beginning of the year in the realm of immunotherapy. Recent headlines have boasted news about some major players making waves in immunotherapy — especially in the NSCLC treatment area —  which will not only benefit a large number of patients, but will also give productive players a slice of what’s expected to be a very lucrative market.  

  3. Pharma News Roundup: Amgen, Isis, Janssen, Pfizer, Novartis, And More 1/14/2015

    In recent news, stem cell research is taking the forefront as new collaborations speed up the development of CRISPR immunotherapies; Cempra is moving forward in its development of a next-generation antibiotic; and a new antisense drug could be a game-changer for autoimmune disorders of the GI tract.

  4. “Pharmaficial” Intelligence: Could Science Fiction Become A Pharma Reality? 1/14/2015

    All the buzz about wearable technology and the convergence of Google and pharma this past year has made me think about where technology is carrying our industry.

  5. FDA Launches Pharma Quality Office To Improve Drug Manufacturing, Agency Teamwork 1/14/2015

    We should expect to see even more attention lavished on pharmaceutical quality in 2015. This week, the FDA announced the launch of its long planned-for Office of Pharmaceutical Quality (OPQ).

  6. Merck Snaps Up Cubist: Will 2015 Be The Antibiotics Renaissance? 1/7/2015

    2014 was a big year for acquisitions. However, two other 2014 acquisitions suggest to me that Big Pharma might be planning to tackle an increasingly urgent unmet health need in 2015.

  7. Will BRICS Have Answers To The HIV Vaccine Search? 1/7/2015

    At the beginning of December, Russia announced it was pushing not just one, but three new HIV vaccines into clinical trials. But Russia is not the only country searching for a successful HIV vaccine as we venture into 2015. 

  8. FDA News Roundup: Amgen, Janssen, Actavis, And More 11/19/2014

    Amgen’s BLA for its cholesterol drug evolocumab was accepted by the FDA for review. Evolocumab is responsible for stopping a key protein, proprotein convertase subtilisin/kexin type 9 (PCSK9), which often halts the removal of “bad cholesterol” from the blood.

  9. FDA News Roundup: Sanofi Pasteur, Ranbaxy, Eli Lilly, And More 11/11/2014

    Isavuconazole has garnered yet another orphan drug designation from the FDA for isavuconazole, this time for the treatment of invasive candidiasis/candidemia.

  10. FDA News Roundup: Baxter, Lundbeck, Daiichi Sankyo, And More 11/4/2014